Federated Explainable AI-Based Alzheimer’s Disease Prediction With Multimodal Data
IEEE Access · 2025 · 13 · 43435-43454
DOI: 10.1109/access.2025.3547343 ↗Kurz gefasst
Fachartikel in der Zeitschrift IEEE Access, 2025. Verfasst von Sobhana Jahan und 7 weiteren Autor:innen. Die Arbeit wurde bisher 51-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Korea Health Technology R&D Project through the Korea Health Industry Development Institute, Ministry of Health & Welfare, Republic of Korea, Woosong University Academic Research Fund, South Korea, in 2025.
Themen: Demenz
Abstract (Originalsprache)
Alzheimer’s Disease (AD) is a progressive neurological disease that severely impairs cognitive function. Early detection is critical for effective treatment and management. Machine Learning (ML) methods are often used to ensure early detection and prediction. However, ML has various issues, including the data island problem. The fragmentation that results from the data island problem makes building reliable, effective ML models more complex, and it is particularly problematic in industries where privacy is a concern, like healthcare. Federated Learning (FL) can help tackle the data island problem by keeping sensitive patient data decentralized and enabling many institutions to work together on model training without exchanging raw data, all while maintaining privacy compliance. As Random Forest (RF) is proven to be the best-performing classifier in this research, an RF classifier is used to create FL. The model incorporates multiple data modalities, such as Magnetic Resonance Imaging (MRI) segmentation and clinical and psychological data, to capture the variety of characteristics influencing the progress of AD. Another concerning issue with ML is its uninterpretable character. We use SHapley Additive exPlanations (SHAP) Explainable Artificial Intelligence (XAI) techniques that emphasize important factors impacting model decisions in order to improve predictability and transparency. This explainability promotes confidence in AI-based diagnoses by enabling researchers and physicians to comprehend the underlying mechanisms guiding the predictions. The combination of XAI, FL, and Open Access Series of Imaging Studies (OASIS-3) Multimodal data offers an interpretable, scalable, reliable, and privacy-centered solution for multiple complex issues, such as predicting AD. This approach results in better diagnosis precision, greater security, and increased confidence in AI technologies, making it a novel methodology in medical sciences. With data privacy maintained, our method produces 98.93% accurate predictions, providing a solid detection strategy for AD. The suggested approach’s F1-score, Precision, Recall, and AUC are 98.93%, 98.94%, 98.93%, and 99.97%, respectively. This work also shows that a multimodal dataset performs better than a single modal dataset.
Förderung
- Korea Health Technology R&D Project through the Korea Health Industry Development Institute
- Ministry of Health & Welfare, Republic of Korea
- Woosong University Academic Research Fund, South Korea, in 2025
Zitieren
APA
Jahan, S., Adib, M. R. S., Huda, S. M., Rahman, M. S., Kaiser, M. S., Hosen, A. S. M. S., Ghimire, D., & Park, M. J. (2025). Federated Explainable AI-Based Alzheimer’s Disease Prediction With Multimodal Data. IEEE Access, 13, 43435-43454. https://doi.org/10.1109/access.2025.3547343
Vancouver
Jahan S, Adib MRS, Huda SM, Rahman MS, Kaiser MS, Hosen ASMS, et al. Federated Explainable AI-Based Alzheimer’s Disease Prediction With Multimodal Data. IEEE Access. 2025;13:43435-43454. doi:10.1109/access.2025.3547343
BibTeX
@article{Jahan2025,
author = {Jahan, Sobhana and Adib, Md. Rawnak Saif and Huda, Syed Mahmudul and Rahman, Md. Sazzadur and Kaiser, M. Shamim and Hosen, A. S. M. Sanwar and Ghimire, Deepak and Park, Mi Jin},
title = {Federated Explainable AI-Based Alzheimer’s Disease Prediction With Multimodal Data},
journal = {IEEE Access},
year = {2025},
volume = {13},
pages = {43435--43454},
doi = {10.1109/access.2025.3547343}
}
EUVIMED